{"filing":{"accession_number":"0001437749-26-030456","cik":"0001625101","ticker":"PLSE","company_name":"PULSE BIOSCIENCES, INC.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-14","primary_document":"plse20260914_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926030456/plse20260914_8k.htm"},"events":[{"id":33669,"run_id":30970,"accession_number":"0001437749-26-030456","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Pulse Biosciences entered into an equity distribution agreement with Mizuho on September 15, 2026, authorizing the sale of up to $85 million in common stock through an at-the-market offering under Rule 415. This follows a prior August 2026 agreement with the same agent under which approximately $68.8 million has already been sold.","company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":37183,"accession_number":"0001437749-26-030456","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Pulse Biosciences entered into an equity distribution agreement with Mizuho on September 15, 2026, authorizing the sale of up to $85 million in common stock through an \"at the market\" offering under Rule 415. This is a dilutive equity issuance arrangement that allows the company to raise capital by selling shares at prevailing market prices. The company has already sold approximately $68.8 million under a prior August 2026 agreement with the same agent, demonstrating active use of this capital-raising mechanism.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T20:45:47.124130+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":33670,"run_id":30970,"accession_number":"0001437749-26-030456","anchor_item_number":"1.02","event_type":"financial_other","event_domain":"financial","is_material":false,"confidence":0.72,"summary":"Pulse Biosciences terminated its at-the-market offering program with TD Securities under an equity distribution agreement dated February 19, 2026, with only $1.0 million in unsold capacity remaining. The termination represents a routine administrative action to end an underutilized program rather than a material capital event.","company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":37184,"accession_number":"0001437749-26-030456","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"financial_other","event_domain":"financial","is_material":false,"confidence":0.72,"reasoning":"The filing discloses termination of an at-the-market (ATM) offering program with TD Securities under an equity distribution agreement dated February 19, 2026. While ATM programs are capital-raising mechanisms, the termination itself—with only $1.0 million in unsold capacity remaining—appears to be a routine administrative action rather than a material capital event. The company is not raising capital through this termination; it is simply ending an underutilized program. This is a financial event but does not rise to the materiality threshold of a dilutive issuance or other capital-raising activity that would affect investor assessment of the registrant's financial position or strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T20:45:47.124130+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37183,"accession_number":"0001437749-26-030456","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Pulse Biosciences entered into an equity distribution agreement with Mizuho on September 15, 2026, authorizing the sale of up to $85 million in common stock through an \"at the market\" offering under Rule 415. This is a dilutive equity issuance arrangement that allows the company to raise capital by selling shares at prevailing market prices. The company has already sold approximately $68.8 million under a prior August 2026 agreement with the same agent, demonstrating active use of this capital-raising mechanism.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T20:45:47.124130+00:00","company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","filing_date":"2026-09-15"},{"id":37184,"accession_number":"0001437749-26-030456","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"financial_other","event_domain":"financial","is_material":false,"confidence":0.72,"reasoning":"The filing discloses termination of an at-the-market (ATM) offering program with TD Securities under an equity distribution agreement dated February 19, 2026. While ATM programs are capital-raising mechanisms, the termination itself—with only $1.0 million in unsold capacity remaining—appears to be a routine administrative action rather than a material capital event. The company is not raising capital through this termination; it is simply ending an underutilized program. This is a financial event but does not rise to the materiality threshold of a dilutive issuance or other capital-raising activity that would affect investor assessment of the registrant's financial position or strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T20:45:47.124130+00:00","company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","filing_date":"2026-09-15"}]}